Quintiles adds TMD to oncology portfolio
This article was originally published in Clinica
Professional healthcare services company Quintiles Transnational has strengthened its oncology offering by purchasing Targeted Molecular Diagnostics (TMD), a laboratory specialising in tissue-based testing. The deal provides Quintiles (Research Triangle Park, North Carolina) with in-house pathology capabilities for tissue-based testing, which the firm describes as being “a critical component of the modern-day oncology drug development process”. According to Quintiles’ senior vice-president Tom Wollman, TMD also gives the company access to important biomarker expression analysis know-how. Westmont, Illinois-based TMD also supports clinical trials for both biotech and pharmaceutical companies around the world, and offers more than 100 biomarker assays. Financial terms of the acquisition were not revealed.